Ligand Pharmaceuticals Q2 2024 Adj. EPS $1.40 Beats $1.06 Estimate, Sales $41.531M Beat $32.865M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals (NASDAQ:LGND) reported Q2 2024 adjusted EPS of $1.40, beating the estimate of $1.06. Sales were $41.531M, surpassing the $32.865M estimate and showing a 57.52% increase from the same period last year.
August 06, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals reported strong Q2 2024 results with EPS of $1.40 beating estimates by 32.08% and sales of $41.531M surpassing estimates by 26.37%. Sales increased by 57.52% YoY.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact LGND's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100